Table Of Contents

1. Market Context & Strategic Relevance

1.1 Opening Context (Why the market matters)

1.1.1 Why This Market Is Gaining Strategic Attention

1.1.2 Business Decisions This Report Supports

1.2 Scope

1.3 Research & Methodology

2. Executive Summary

2.1 Market Snapshot

2.2 Market Absolute $ Opportunity Assessment & Y-o-Y Analysis, 2022-2035

2.3 Market Size & Forecast, By Segmentation, 2022-2035

2.3.1 Market Size By Isotope Type

2.3.2 Market Size By Therapy Type

2.3.3 Market Size By Indication

2.3.4 Market Size By End User

2.4 Market Share & Bps Analysis By Region, 2025

2.5 Industry Growth Scenarios - Conservative, Likely & Optimistic

2.6 Industry CxO's Perspective

3. Market Overview

3.1 Market Dynamics

3.1.1 Drivers

3.1.2 Restraints

3.1.3 Opportunities

3.1.4 Key Market Trends

3.2 Industry PESTLE Analysis

3.3 Key Industry Forces (Porter's) Impacting Market Growth

3.4 Industry Supply Chain Analysis

3.4.1 Isotope Producers & Radioisotope Suppliers

3.4.2 Radioligand & Radioimmunoconjugate Manufacturers

3.4.3 Clinical-Stage & Commercial Drug Developers

3.4.4 End Users (Hospitals, Cancer Centers, Specialty Clinics)

3.5 Industry Life Cycle Assessment

4. Statistical Insights & Trends Reporting

4.1 Clinical & Pipeline Metrics

4.1.1 Number of Active Clinical Trials Utilizing Alpha-Emitter Isotopes (Count)

4.1.2 Number of Alpha-Emitter Candidates in Phase III Development (Count)

4.1.3 Average Objective Response Rate Across Key Alpha Therapy Trials (%)

4.1.4 Breakthrough & Fast-Track Designations Granted to Alpha Therapies (Count)

4.1.5 Average Clinical Development Timeline From Phase I to Approval (Years)

4.2 Production & Supply Metrics

4.2.1 Global Annual Production Capacity of Key Alpha-Emitting Isotopes (Millicuries/Year)

4.2.2 Percentage of Global Isotope Supply From Government vs. Commercial Producers (%)

4.2.3 Average Isotope Production Lead Time by Method (Days)

4.3 Commercial & Pricing Metrics

4.3.1 Average Cost Per Treatment Cycle of Alpha-Emitter Radiopharmaceuticals (USD)

4.3.2 Number of Approved Alpha-Emitter Radiopharmaceutical Products (Count)

4.3.3 Payer Reimbursement Coverage Rate for Approved Alpha Therapies (%)

4.4 Supply Chain & Logistics Indicators

4.4.1 Average Distribution Time From Production Site to Treatment Center (Hours)

4.4.2 Percentage of Facilities With On-Site Radiopharmacy Capability (%)

4.4.3 Average Global Isotope Supply-Demand Gap (Millicuries/Year)

5. Targeted Alpha Therapy Market Segmental Analysis & Forecast, By Isotope Type, 2022-2035, Value (USD Million)

5.1 Introduction

5.2 Actinium-225

5.2.1 Key Trends

5.2.2 Market Size & Forecast, 2022-2035

5.3 Radium-223

5.4 Lead-212

5.5 Bismuth-213

5.6 Others

6. Targeted Alpha Therapy Market Segmental Analysis & Forecast, By Therapy Type, 2022-2035, Value (USD Million)

6.1 Introduction

6.2 Radioligand Therapy

6.2.1 Key Trends

6.2.2 Market Size & Forecast, 2022-2035

6.3 Radioimmunotherapy

6.4 Diagnostic & Theranostic Use

7. Targeted Alpha Therapy Market Segmental Analysis & Forecast, By Indication, 2022-2035, Value (USD Million)

7.1 Introduction

7.2 Prostate Cancer

7.2.1 Key Trends

7.2.2 Market Size & Forecast, 2022-2035

7.3 Neuroendocrine Tumors

7.4 Leukemia & Hematologic Malignancies

7.5 Bone Metastases

7.6 Others

8. Targeted Alpha Therapy Market Segmental Analysis & Forecast, By End User, 2022-2035, Value (USD Million)

8.1 Introduction

8.2 Hospitals & Cancer Treatment Centers

8.2.1 Key Trends

8.2.2 Market Size & Forecast, 2022-2035

8.3 Specialty Oncology Clinics & Radiopharmacies

8.4 Research & Academic Institutes

9. Targeted Alpha Therapy Market Segmental Analysis & Forecast By Region, 2022-2035, Value (USD Million)

9.1 Introduction

9.2 North America

9.2.1 Key Trends

9.2.2 Targeted Alpha Therapy Market Size & Forecast, By Isotope Type, 2022-2035

9.2.3 Targeted Alpha Therapy Market Size & Forecast, By Therapy Type, 2022-2035

9.2.4 Targeted Alpha Therapy Market Size & Forecast, By Indication, 2022-2035

9.2.5 Targeted Alpha Therapy Market Size & Forecast, By End User, 2022-2035

9.2.6 Targeted Alpha Therapy Market Size & Forecast, By Country, 2022-2035

9.2.6.1 USA

9.2.6.2 Canada

9.3 Europe

9.3.1 Key Trends

9.3.2 Targeted Alpha Therapy Market Size & Forecast, By Isotope Type, 2022-2035

9.3.3 Targeted Alpha Therapy Market Size & Forecast, By Therapy Type, 2022-2035

9.3.4 Targeted Alpha Therapy Market Size & Forecast, By Indication, 2022-2035

9.3.5 Targeted Alpha Therapy Market Size & Forecast, By End User, 2022-2035

9.3.6 Targeted Alpha Therapy Market Size & Forecast, By Country, 2022-2035

9.3.6.1 Germany

9.3.6.2 UK

9.3.6.3 France

9.3.6.4 Italy

9.3.6.5 Spain

9.3.6.6 Russia

9.3.6.7 Poland

9.3.6.8 Rest of Europe

9.4 Asia Pacific

9.4.1 Key Trends

9.4.2 Targeted Alpha Therapy Market Size & Forecast, By Isotope Type, 2022-2035

9.4.3 Targeted Alpha Therapy Market Size & Forecast, By Therapy Type, 2022-2035

9.4.4 Targeted Alpha Therapy Market Size & Forecast, By Indication, 2022-2035

9.4.5 Targeted Alpha Therapy Market Size & Forecast, By End User, 2022-2035

9.4.6 Targeted Alpha Therapy Market Size & Forecast, By Country, 2022-2035

9.4.6.1 China

9.4.6.2 India

9.4.6.3 Japan

9.4.6.4 South Korea

9.4.6.5 Australia

9.4.6.6 ASEAN Countries

9.4.6.7 Rest of Asia-Pacific

9.5 Latin America

9.5.1 Key Trends

9.5.2 Targeted Alpha Therapy Market Size & Forecast, By Isotope Type, 2022-2035

9.5.3 Targeted Alpha Therapy Market Size & Forecast, By Therapy Type, 2022-2035

9.5.4 Targeted Alpha Therapy Market Size & Forecast, By Indication, 2022-2035

9.5.5 Targeted Alpha Therapy Market Size & Forecast, By End User, 2022-2035

9.5.6 Targeted Alpha Therapy Market Size & Forecast, By Country, 2022-2035

9.5.6.1 Brazil

9.5.6.2 Argentina

9.5.6.3 Mexico

9.5.6.4 Colombia

9.5.6.5 Rest of Latin America

9.6 Middle East & Africa

9.6.1 Key Trends

9.6.2 Targeted Alpha Therapy Market Size & Forecast, By Isotope Type, 2022-2035

9.6.3 Targeted Alpha Therapy Market Size & Forecast, By Therapy Type, 2022-2035

9.6.4 Targeted Alpha Therapy Market Size & Forecast, By Indication, 2022-2035

9.6.5 Targeted Alpha Therapy Market Size & Forecast, By End User, 2022-2035

9.6.6 Targeted Alpha Therapy Market Size & Forecast, By Country, 2022-2035

9.6.6.1 UAE

9.6.6.2 Saudi Arabia

9.6.6.3 Qatar

9.6.6.4 South Africa

9.6.6.5 Rest of Middle East & Africa

10. Competitive Landscape

10.1 Key Players' Positioning

10.2 Competitive Developments

10.2.1 Year-Wise Strategies & Development, 2022-2026

10.3 Market Share Analysis, 2025

10.4 Product/Service & Application Benchmarking

10.4.1 Product/Service Specifications & Features By Key Players

10.4.2 Product/Service Heatmap By Key Players

10.4.3 Application Heatmap By Key Players

10.5 Industry Start-Up & Innovation Landscape

10.6 Key Company Profiles

10.6.1 Novartis AG

10.6.1.1 Company Overview & Snapshot

10.6.1.2 Product/Service Portfolio

10.6.1.3 Key Company Financials

10.6.1.4 Geographical Presence

10.6.1.5 SWOT Analysis

10.6.2 Bayer AG

10.6.3 Telix Pharmaceuticals Limited

10.6.4 Fusion Pharmaceuticals Inc. (AstraZeneca)

10.6.5 Eli Lilly and Company

10.6.6 Bristol Myers Squibb Company

10.6.7 Orano Med

10.6.8 Sanofi

10.6.9 Convergent Therapeutics, Inc.

10.6.10 AdvanCell

10.6.11 Actinium Pharmaceuticals, Inc.

10.6.12 Perspective Therapeutics, Inc.

10.6.13 Ratio Therapeutics

10.6.14 Aktis Oncology

10.6.15 NorthStar Medical Radioisotopes, LLC

10.6.16 Eckert & Ziegler Radiopharma GmbH

10.6.17 ITM Isotope Technologies Munich SE

10.6.18 Ion Beam Applications SA (IBA)

10.6.19 Cardinal Health, Inc.

10.6.20 Curium Pharma

11. Analyst Recommendations

11.1 SNS Insider Opportunity Map

11.2 Industry Low-Hanging Fruit Assessment

11.3 Market Entry & Growth Strategy

11.4 Analyst Viewpoint & Suggestions On Market Growth

12. Assumptions

13. Disclaimer

14. Appendix

14.1 List Of Tables

14.2 List Of Figures